-
Company Insights
New![]()
Innovation and Patenting activity of Ocugen Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ocugen Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Net Present Value Model: Ocugen Inc’s OCU-400
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Unity Biotechnology Inc’s UBX-1325
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OCU-410 in Dry (Atrophic) Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OCU-410 in Dry (Atrophic) Macular Degeneration Drug Details: OCU-410 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OCU-410ST in Juvenile Macular Degeneration (Stargardt Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OCU-410ST in Juvenile Macular Degeneration (Stargardt Disease) Drug Details: OCU-410ST is under the development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STP-1 in Autism Spectrum Disorder (ASD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STP-1 in Autism Spectrum Disorder (ASD) Drug Details: STP-1 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-600 in Squamous Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-600 in Squamous Non-Small Cell Lung CancerDrug Details:VTP-600 is under development for the treatment of non-squamous...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-203 in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-203 in Small-Cell Lung Cancer Drug Details: AV-203 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OCU-400 in Leber Congenital Amaurosis (LCA)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OCU-400 in Leber Congenital Amaurosis (LCA) Drug Details:OCU-400 is under development for the treatment of inherited...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OCU-400 in Retinitis Pigmentosa (Retinitis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OCU-400 in Retinitis Pigmentosa (Retinitis) Drug Details:OCU-400 is under development for the treatment of inherited degenerative...
-
Product Insights
![]()
Cartilage Repair Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Cartilage Repair Pipeline Market Report Overview Cartilage repair procedures aim to regenerate, restore or replace articular cartilage to reduce joint pain and to prevent the development of arthritis. Cartilage repair interventions can occur early in the spectrum of joint damage and offer an opportunity for patients to delay or altogether avoid needing total joint replacement surgery. The cartilage repair pipeline market research report provides comprehensive information about the cartilage repair pipeline products with a comparative analysis of the products at...
-
Company Profile
![]()
Ocugen Inc – Company Profile
Ocugen Inc (Ocugen) Is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment. It is investigating OCU-400 against NR2E3, RHO, CEP290, and PDE6B mutation-associated retinal degeneration, and OCU-410 targeting dry age-related macular degeneration. The company is developing OCU200 drugs to treat diabetic macular edema, diabetic retinopathy, and wet-age-related macular degeneration. Ocugen is also investing OCU410ST for stargardt orphan disease. It utilizes a modified gene therapy platform to develop its products. The company operates in Ireland and the US....
Add to Basket -
Product Insights
![]()
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
![]()
Net Present Value Model: Covaxin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Covaxin Drug Details Coronavirus Disease 2019...
-
Product Insights
![]()
Net Present Value Model: OCU-400
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model OCU-400 Drug Details OCU-400 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – OCU-400
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OCU-400 Drug Details OCU-400 is under development for the treatment of inherited degenerative retinal...
-
Product Insights
![]()
Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic Retinopathy Drugs Market Report Overview Diabetic retinopathy is a complication of diabetes that affects the eyes. The symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The Diabetic Retinopathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Sector Analysis
![]()
Orthobiologics Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Orthobiologics are biomaterials used in orthopedic surgery as an adjunct to faster fusion and healing of the bone. The orthobiologics category covers bone graft substitutes, bone growth stimulators, cartilage repair and viscosupplementation products. The orthobiologics pipeline market research report provides comprehensive information about the orthobiologics pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
![]()
Leber Congenital Amaurosis (LCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leber Congenital Amaurosis (LCA) is the most common cause of inherited blindness in childhood. Its symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. The Leber Congenital Amaurosis pipeline market research report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of...
-
Product Insights
![]()
Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes. The Diabetic Macular Edema drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.